Zn and Ni doping effects on the low-energy spin excitations in La1.85_{1.85}Sr0.15_{0.15}CuO4_{4}

Impurity effects of Zn and Ni on the low-energy spin excitations were systematically studied in optimally doped La1.85Sr0.15Cu1-yAyO4 (A=Zn, Ni) by neutron scattering. Impurity-free La1.85Sr0.15CuO4 shows a spin gap of 4meV below Tc in the antiferromagnetic(AF) incommensurate spin excitation. In Zn:y=0.004, the spin excitation shows a spin gap of 3meV below Tc. In Zn:y=0.008 and Zn:y=0.011, however, the magnetic signals at 3meV decrease below Tc and increase again at lower temperature, indicating an in-gap state. In Zn:y=0.017, the low-energy spin state remains unchanged with decreasing temperature, and elastic magnetic peaks appear below 20K then exponentially increase. As for Ni:y=0.009 and Ni:y=0.018, the low-energy excitations below 3meV and 2meV disappear below Tc. The temperature dependence at 3meV, however, shows no upturn in constrast with Zn:y=0.008 and Zn:y=0.011, indicating the absence of in-gap state. In Ni:y=0.029, the magnetic signals were observed also at 0meV. Thus the spin gap closes with increasing Ni. Furthermore, as omega increases, the magnetic peak width broadens and the peak position, i.e. incommensurability, shifts toward the magnetic zone center (pi pi). We interpret the impurity effects as follows: Zn locally makes a non-superconducting island exhibiting the in-gap state in the superconducting sea with the spin gap. Zn reduces the superconducting volume fraction, thus suppressing Tc. On the other hand, Ni primarily affects the superconducting sea, and the spin excitations become more dispersive and broaden with increasing energy, which is recognized as a consequence of the reduction of energy scale of spin excitations. We believe that the reduction of energy scale is relevant to the suppression of Tc.Comment: 13pages, 14figures; submitted to Phys. Rev.

Widespread seismicity excitation throughout central Japan following the 2011 M=9.0 Tohoku earthquake and its interpretation by Coulomb stress transfer

Author Posting. © American Geophysical Union, 2011. This article is posted here by permission of American Geophysical Union for personal use, not for redistribution. The definitive version was published in Geophysical Research Letters 38 (2011): L00G03, doi:10.1029/2011GL047834.We report on a broad and unprecedented increase in seismicity rate following the M=9.0 Tohoku mainshock for M ≥ 2 earthquakes over inland Japan, parts of the Japan Sea and Izu islands, at distances of up to 425 km from the locus of high (≥15 m) seismic slip on the megathrust. Such an increase was not seen for the 2004 M=9.1 Sumatra or 2010 M=8.8 Chile earthquakes, but they lacked the seismic networks necessary to detect such small events. Here we explore the possibility that the rate changes are the product of static Coulomb stress transfer to small faults. We use the nodal planes of M ≥ 3.5 earthquakes as proxies for such small active faults, and find that of fifteen regions averaging ∼80 by 80 km in size, 11 show a positive association between calculated stress changes and the observed seismicity rate change, 3 show a negative correlation, and for one the changes are too small to assess. This work demonstrates that seismicity can turn on in the nominal stress shadow of a mainshock as long as small geometrically diverse active faults exist there, which is likely quite common

Radiotherapy for neovascular age-related macular degeneration

BACKGROUND: Radiotherapy has been proposed as a treatment for new vessel growth in people with neovascular age-related macular degeneration (AMD). OBJECTIVES: To examine the effects of radiotherapy on neovascular AMD. SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, LILACS and three trials registers and checked references of included studies. We last searched the databases on 4 May 2020.  SELECTION CRITERIA: We included all randomised controlled trials in which radiotherapy was compared to another treatment, sham treatment, low dosage irradiation or no treatment in people with choroidal neovascularisation (CNV) secondary to AMD. DATA COLLECTION AND ANALYSIS: We used standard procedures expected by Cochrane. We graded the certainty of the evidence using GRADE. We considered the following outcomes at 12 months: best-corrected visual acuity (BCVA) (loss of 3 or more lines, change in visual acuity), contrast sensitivity, new vessel growth, quality of life and adverse effects at any time point.  MAIN RESULTS: We included 18 studies (n = 2430 people, 2432 eyes) of radiation therapy with dosages ranging from 7.5 to 24 Gy. These studies mainly took place in Europe and North America but two studies were from Japan and one multicentre study included sites in South America. Three of these studies investigated brachytherapy (plaque and epimacular), the rest were studies of external beam radiotherapy (EBM) including one trial of stereotactic radiotherapy. Four studies compared radiotherapy combined with anti-vascular endothelial growth factor (anti-VEGF) with anti-VEGF alone. Eleven studies gave no radiotherapy treatment to the control group; five studies used sham irradiation; and one study used very low-dose irradiation (1 Gy). One study used a mixture of sham irradiation and no treatment. Fifteen studies were judged to be at high risk of bias in one or more domains. Radiotherapy versus no radiotherapy There may be little or no difference in loss of 3 lines of vision at 12 months in eyes treated with radiotherapy compared with no radiotherapy (risk ratio (RR) 0.82, 95% confidence interval (CI) 0.64 to 1.04, 811 eyes, 8 studies, I2 = 66%, low-certainty evidence). Low-certainty evidence suggests a small benefit in change in visual acuity (mean difference (MD) -0.10 logMAR, 95% CI -0.17 to -0.03; eyes = 883; studies = 10) and average contrast sensitivity at 12 months (MD 0.15 log units, 95% CI 0.05 to 0.25; eyes = 267; studies = 2). Growth of new vessels (largely change in CNV size) was variably reported and It was not possible to produce a summary estimate of this outcome. The studies were small with imprecise estimates and there was no consistent pattern to the study results (very low-certainty evidence). Quality of life was only reported in one study of 199 people; there was no clear difference between treatment and control groups (low-certainty evidence). Low-certainty evidence was available on adverse effects from eight of 14 studies. Seven studies reported on radiation retinopathy and/or neuropathy. Five of these studies reported no radiation-associated adverse effects. One study of 88 eyes reported one case of possible radiation retinopathy. One study of 74 eyes graded retinal abnormalities in some detail and found that 72% of participants who had radiation compared with 71% of participants in the control group had retinal abnormalities resembling radiation retinopathy or choroidopathy. Four studies reported cataract surgery or progression: events were generally few with no consistent evidence of any increased occurrence in the radiation group. One study noted transient disturbance of the precorneal tear film but there was no evidence from the other two studies that reported dry eye of any increased risk with radiation therapy. None of the participants received anti-VEGF injections. Radiotherapy combined with anti-VEGF versus anti-VEGF alone People receiving radiotherapy/anti-VEGF were probably more likely to lose 3 or more lines of BCVA at 12 months compared with anti-VEGF alone (RR 2.11, 95% CI 1.40 to 3.17, 1050 eyes, 3 studies, moderate-certainty). Most of the data for this outcome come from two studies of epimacular brachytherapy (114 events) compared with 20 events from the one trial of EBM. Data on change in BCVA were heterogenous (I2 = 82%). Individual study results ranged from a small difference of -0.03 logMAR in favour of radiotherapy/anti-VEGF to a difference of 0.13 logMAR in favour of anti-VEGF alone (low-certainty evidence). The effect differed depending on how the radiotherapy was delivered (test for interaction P = 0.0007). Epimacular brachytherapy was associated with worse visual outcomes (MD 0.10 logMAR, 95% CI 0.05 to 0.15, 820 eyes, 2 studies) compared with EBM (MD -0.03 logMAR, 95% CI -0.09 to 0.03, 252 eyes, 2 studies). None of the included studies reported contrast sensitivity or quality of life. Growth of new vessels (largely change in CNV size) was variably reported in three studies (803 eyes). It was not possible to produce a summary estimate and there was no consistent pattern to the study results (very low-certainty evidence). For adverse outcomes, variable results were reported in the four studies. In three studies reports of adverse events were low and no radiation-associated adverse events were reported. In one study of epimacular brachytherapy there was a higher proportion of ocular adverse events (54%) compared to the anti-VEGF alone (18%). The majority of these adverse events were cataract. Overall 5% of the treatment group had radiation device-related adverse events (17 cases); 10 of these cases were radiation retinopathy. There were differences in average number of injections given between the four studies (1072 eyes). In three of the four studies, the anti-VEGF alone group on average received more injections (moderate-certainty evidence). AUTHORS' CONCLUSIONS: The evidence is uncertain regarding the use of radiotherapy for neovascular AMD. Most studies took place before the routine use of anti-VEGF, and before the development of modern radiotherapy techniques such as stereotactic radiotherapy. Visual outcomes with epimacular brachytherapy are likely to be worse, with an increased risk of adverse events,  probably related to vitrectomy. The role of stereotactic radiotherapy combined with anti-VEGF is currently uncertain. Further research on radiotherapy for neovascular AMD may not be justified until current ongoing studies have reported their results

Application of Glass Fiber and Carbon Fiber-Reinforced Thermoplastics in Face Guards

Face guards (FGs) are protectors that allow for the rapid and safe return of athletes who are to play after sustaining traumatic facial injuries and orbital fractures. Current FGs require significant thickness to achieve sufficient shock absorption abilities. However, their weight and thickness render the FGs uncomfortable and reduce the field of vision of the athlete, thus hindering their performance. Therefore, thin and lightweight FGs are required. We fabricated FGs using commercial glass fiber-reinforced thermoplastic (GFRTP) and carbon fiber-reinforced thermoplastic (CFRTP) resins to achieve these requirements and investigated their shock absorption abilities through impact testing. The results showed that an FG composed of CFRTP is thinner and lighter than a conventional FG and has sufficient shock absorption ability. The fabrication method of an FG comprising CFRTP is similar to the conventional method. FGs composed of commercial FRTPs exhibit adequate shock absorption abilities and are thinner and lower in weight as compared to conventional FGs

Development of a Wearable Mouth Guard Device for Monitoring Teeth Clenching during Exercise

Teeth clenching during exercise is important for sports performance and health. Recently, several mouth guard (MG)-type wearable devices for exercise were studied because they do not disrupt the exercise. In this study, we developed a wearable MG device with force sensors on both sides of the maxillary first molars to monitor teeth clenching. The force sensor output increased linearly up to 70 N. In four simple occlusion tests, the trends exhibited by the outputs of the MG sensor were consistent with those of an electromyogram (EMG), and the MG device featured sufficient temporal resolution to measure the timing of teeth clenching. When the jaw moved, the MG sensor outputs depended on the sensor position. The MG sensor output from the teeth-grinding test agreed with the video-motion analysis results. It was comparatively difficult to use the EMG because it contained a significant noise level. Finally, the usefulness of the MG sensor was confirmed through an exercise tolerance test. This study indicated that the developed wearable MG device is useful for monitoring clenching timing and duration, and the degree of clenching during exercise, which can contribute to explaining the relationship between teeth clenching and sports performance

Improvement of the Shock Absorption Ability of a Face Guard by Incorporating a Glass-Fiber-Reinforced Thermoplastic and Buffering Space

This study aimed to evaluate the shock absorption ability of trial face guards (FGs) incorporating a glass-fiber-reinforced thermoplastic (GF) and buffering space. The mechanical properties of 3.2 mm and 1.6 mm thick commercial medical splint materials (Aquaplast, AP) and experimental GF prepared from 1.6 mm thick AP and fiberglass cloth were determined by a three-point bending test. Shock absorption tests were conducted on APs with two different thicknesses and two types of experimental materials, both with a bottom material of 1.6 mm thick AP and a buffering space of 30 mm in diameter (APS) and with either (i) 1.6 mm thick AP (AP-APS) or (ii)  1.6 mm thick GF (GF-APS) covering the APS. The GF exhibited significantly higher flexural strength (64.4 MPa) and flexural modulus (7.53 GPa) than the commercial specimens. The maximum load of GF-APS was 75% that of 3.2 mm AP, which is widely used clinically. The maximum stress of the GF-APS only could not be determined as its maximum stress is below the limits of the analysis materials used (<0.5 MPa). Incorporating a GF and buffering space would enhance the shock absorption ability; thus, the shock absorption ability increased while the total thickness and weight decreased